Optic nerve head plasmacytoma as a manifestation of multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33767963/
Extramedullary disease in multiple myeloma is uncommon and associated with a poorer prognosis. Extramedullary disease involving the orbit is even more unusual, with optic nerve involvement being rare. We describe...
-
Mark Fesler4yrThe head and neck region seems to be a common site of extramedullary myeloma /plasmacytoma involvement for reasons that I’m not sure are well understood
FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma
The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has...
-
Mark Fesler4yrThis is a very exciting advance for the field of myeloma and ushers in a new era of treatment Existing treatment algorithms will require modification
Targeting SIRT1 to inhibit the proliferation of multiple myeloma cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33732382/
Multiple myeloma (MM) is the second most common hematopoietic malignancy and remains an incurable disease. Thus, novel drugs and therapeutic methods are required for patients with MM. The present study...
2020 FDA TIDES (Peptides and Oligonucleotides) Harvest
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918236/
2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling...
Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma
Source : https://academic.oup.com/clinchem/advance-article-abstract/doi/10.1093/clinchem/hvab017/6168671
AbstractBackground. Due to improved treatment, more patients with multiple myeloma (MM) reach a state of minimal residual disease (MRD). Different strategies fo